Mounjaro, the breakthrough obesity and diabetes drug from Eli Lilly and Company, has become India’s highest-selling pharmaceutical brand in October, according to fresh data from market intelligence firm Pharmarack released on November 7.
The blockbuster medication, which contains tirzepatide as its active ingredient, recorded sales worth Rs100 crore last month, surpassing long-time market leader Augmentin, the antibiotic
Continue Reading on India Today
This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.